The expectations of the developers of a potential corona vaccine are high. The Mainz-based company Biontech and its US partner Pfizer are already on the home straight, they want to submit a means for approval to the authorities in a few weeks. The tests are running under high pressure.
Mainz-based Biontech SE and the US pharmaceutical company Pfizer want to expand their vaccine study in the USA. As the companies jointly announced, they have applied to the US Food and Drug Administration to expand the phase 3 study of their experimental Covid-19 vaccine to 44,000 subjects from the previous 30,000. That number should be reached in the coming week.
The broader field of test subjects should also include younger people aged 16 and over. People suffering from viral diseases such as HIV and hepatitis C and B should also be taken into account.
Biontech and its US partner Pfizer are among the leading companies in the race for a corona vaccine. Pfizer and Biontech expect to have results by October. If the results are positive, the drug should be submitted to the authorities for approval at the end of October. Up to 100 million units of the vaccine are expected to be manufactured worldwide by the end of 2020 and around 1.3 billion by the end of 2021.
Last week, Biontech announced a cooperation with the drug manufacturer Dermapharm in the production of its potential corona vaccine. If the vaccine is approved, Dermapharm will make production capacities in Germany as well as filling and packaging available and also expand them. That gave the Dermapharm share a boost.
.